Derik De Bruin
Stock Analyst at B of A Securities
(4.57)
# 218
Out of 4,962 analysts
217
Total ratings
64.38%
Success rate
15.14%
Average return
Main Sectors:
Stocks Rated by Derik De Bruin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RVTY Revvity | Maintains: Buy | $116 → $110 | $92.14 | +19.38% | 3 | Jun 26, 2025 | |
| BRKR Bruker | Maintains: Buy | $61 → $50 | $34.61 | +44.47% | 13 | Jun 26, 2025 | |
| TXG 10x Genomics | Maintains: Neutral | $12 → $13 | $14.07 | -7.60% | 9 | Jun 26, 2025 | |
| QGEN Qiagen | Maintains: Buy | $50 → $53 | $48.90 | +8.38% | 6 | Jun 26, 2025 | |
| MTD Mettler-Toledo International | Maintains: Neutral | $1,200 → $1,260 | $1,289.78 | -2.31% | 10 | Jun 26, 2025 | |
| WAT Waters | Maintains: Neutral | $370 → $375 | $298.95 | +25.44% | 14 | Jun 26, 2025 | |
| A Agilent Technologies | Maintains: Neutral | $156 → $128 | $119.15 | +7.43% | 33 | Apr 14, 2025 | |
| MYGN Myriad Genetics | Maintains: Underperform | $13 → $11 | $5.91 | +86.28% | 13 | Mar 3, 2025 | |
| EXAS Exact Sciences | Maintains: Buy | $72 → $65 | $45.66 | +42.36% | 7 | Feb 20, 2025 | |
| NEO NeoGenomics | Maintains: Neutral | $19 → $16 | $6.45 | +148.06% | 5 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $675 → $660 | $490.75 | +34.49% | 18 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $255 → $235 | $188.02 | +24.99% | 3 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $220 → $210 | $164.11 | +27.96% | 5 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $350 → $355 | $247.21 | +43.60% | 7 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $24 → $26 | $21.99 | +18.24% | 4 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $262 → $271 | $276.11 | -1.85% | 8 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $179 → $182 | $178.66 | +1.87% | 5 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $290 | $207.73 | +39.60% | 4 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $13 → $15 | $31.94 | -53.04% | 4 | Aug 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $26 → $21 | $8.86 | +137.02% | 5 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $38 → $32 | $19.54 | +63.77% | 1 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $140 → $100 | $99.66 | +0.34% | 11 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $94 → $86 | $67.13 | +28.11% | 11 | Aug 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $13 | $3.57 | +264.15% | 1 | Jun 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $9 → $6.5 | $2.10 | +209.52% | 1 | Jan 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $265 → $260 | $171.75 | +51.38% | 1 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $240 → $120 | $12.05 | +895.85% | 3 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $111 → $120 | $155.19 | -22.68% | 2 | Jul 1, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $10 → $9 | $2.18 | +312.84% | 7 | May 8, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $275 → $235 | $641.35 | -63.36% | 3 | Nov 2, 2018 |
Revvity
Jun 26, 2025
Maintains: Buy
Price Target: $116 → $110
Current: $92.14
Upside: +19.38%
Bruker
Jun 26, 2025
Maintains: Buy
Price Target: $61 → $50
Current: $34.61
Upside: +44.47%
10x Genomics
Jun 26, 2025
Maintains: Neutral
Price Target: $12 → $13
Current: $14.07
Upside: -7.60%
Qiagen
Jun 26, 2025
Maintains: Buy
Price Target: $50 → $53
Current: $48.90
Upside: +8.38%
Mettler-Toledo International
Jun 26, 2025
Maintains: Neutral
Price Target: $1,200 → $1,260
Current: $1,289.78
Upside: -2.31%
Waters
Jun 26, 2025
Maintains: Neutral
Price Target: $370 → $375
Current: $298.95
Upside: +25.44%
Agilent Technologies
Apr 14, 2025
Maintains: Neutral
Price Target: $156 → $128
Current: $119.15
Upside: +7.43%
Myriad Genetics
Mar 3, 2025
Maintains: Underperform
Price Target: $13 → $11
Current: $5.91
Upside: +86.28%
Exact Sciences
Feb 20, 2025
Maintains: Buy
Price Target: $72 → $65
Current: $45.66
Upside: +42.36%
NeoGenomics
Feb 19, 2025
Maintains: Neutral
Price Target: $19 → $16
Current: $6.45
Upside: +148.06%
Dec 13, 2024
Maintains: Buy
Price Target: $675 → $660
Current: $490.75
Upside: +34.49%
Dec 13, 2024
Maintains: Buy
Price Target: $255 → $235
Current: $188.02
Upside: +24.99%
Dec 13, 2024
Maintains: Neutral
Price Target: $220 → $210
Current: $164.11
Upside: +27.96%
Dec 13, 2024
Maintains: Buy
Price Target: $350 → $355
Current: $247.21
Upside: +43.60%
Dec 13, 2024
Maintains: Buy
Price Target: $24 → $26
Current: $21.99
Upside: +18.24%
Dec 13, 2024
Maintains: Buy
Price Target: $262 → $271
Current: $276.11
Upside: -1.85%
Dec 13, 2024
Maintains: Buy
Price Target: $179 → $182
Current: $178.66
Upside: +1.87%
Dec 13, 2024
Upgrades: Buy
Price Target: $290
Current: $207.73
Upside: +39.60%
Aug 30, 2024
Maintains: Underperform
Price Target: $13 → $15
Current: $31.94
Upside: -53.04%
Aug 13, 2024
Maintains: Underperform
Price Target: $26 → $21
Current: $8.86
Upside: +137.02%
Feb 29, 2024
Maintains: Neutral
Price Target: $38 → $32
Current: $19.54
Upside: +63.77%
Dec 12, 2023
Downgrades: Underperform
Price Target: $140 → $100
Current: $99.66
Upside: +0.34%
Aug 1, 2023
Maintains: Neutral
Price Target: $94 → $86
Current: $67.13
Upside: +28.11%
Jun 16, 2023
Downgrades: Neutral
Price Target: $13
Current: $3.57
Upside: +264.15%
Jan 4, 2023
Downgrades: Underperform
Price Target: $9 → $6.5
Current: $2.10
Upside: +209.52%
Nov 9, 2022
Upgrades: Buy
Price Target: $265 → $260
Current: $171.75
Upside: +51.38%
May 18, 2022
Downgrades: Underperform
Price Target: $240 → $120
Current: $12.05
Upside: +895.85%
Jul 1, 2019
Downgrades: Neutral
Price Target: $111 → $120
Current: $155.19
Upside: -22.68%
May 8, 2019
Reiterates: Underperform
Price Target: $10 → $9
Current: $2.18
Upside: +312.84%
Nov 2, 2018
Maintains: Buy
Price Target: $275 → $235
Current: $641.35
Upside: -63.36%